Prostate Cancer Clinical Trial
— DARANAOfficial title:
Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation
Verified date | August 2017 |
Source | The Netherlands Cancer Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Rationale: Understanding the mechanisms of enzalutamide as an androgen receptor inhibitor in
early prostate cancer could lead to improved patient selection for treatment.
Objective: To study the effects of enzalutamide on surgical margin status and AR / DNA
interaction and gene expression.
Intervention : Men with localized prostate cancer will undergo an additional set of targeted
tumor biopsies and will be subsequently treated with 3 months of enzalutamide. The
prostatectomy specimen will be additionally sampled, ex vivo.
Status | Completed |
Enrollment | 50 |
Est. completion date | April 1, 2017 |
Est. primary completion date | April 1, 2017 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Men over 18 years of age. 2. clinically non-metastasized prostate cancer, tumor that can be imaged (TRUS or MRI) in order to allow for accurate preoperative biopsies. 3. Gleason score 7-10 4. written informed consent 5. WHO performance 0-1 Exclusion Criteria: 1. A history of seizures. 2. Clinically nodal metastases. 3. Prostatitis or urinary tract infection. 4. Androgen ablative therapy within 6 weeks of inclusion (including 5 alpha-reductase inhibitors). 5. Tumor of the prostate that can not be visualized by TRUS or MRI. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
The Netherlands Cancer Institute | Astellas Pharma Inc |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Effects of enzalutamide on tumor downstaging | To study the effects of enzalutamide on surgical margin status and AR / DNA interaction and gene expression. | From baseline (prior to treatment), until disease progression or as long as treatment is tolerated or until study completion (60 months). | |
Primary | Genetic and transcriptional changes caused by enzalutamide | The genetic and transcriptional changes caused by neoadjuvant androgen ablation by enzalutamide. | From baseline (prior to treatment), until disease progression or as long as treatment is tolerated or until study completion (60 months). | |
Secondary | Clinical down-staging of enzalutamide pretreatment | To assess the effects of 3 months enzalutamide pretreatment on clinical down-staging | From baseline (prior to treatment), until disease progression or as long as treatment is tolerated or until study completion (60 months). | |
Secondary | AR-chromatin binding alterations and Ki-67 expression | Study the correlation between AR-chromatin binding alterations and Ki-67 expression. | From baseline (prior to treatment), until disease progression or as long as treatment is tolerated or until study completion (60 months). | |
Secondary | AR-dependant genes such as PSA, human kallikrein and PSMA | Compare the AR-chromatin binding with expression alterations of known AR-dependent genes such as PSA, human kallikrein and PSMA. | From baseline (prior to treatment), until disease progression or as long as treatment is tolerated or until study completion (60 months). | |
Secondary | Gleason grading | Compare AR-chromatin binding patterns with Gleason grading. | From baseline (prior to treatment), until disease progression or as long as treatment is tolerated or until study completion (60 months). | |
Secondary | Find associated genes in prostate tissue, using tissue microarray (TMA). | Find associated genes on TMA derived from prostatectomy specimens. | From baseline (prior to treatment), until disease progression or as long as treatment is tolerated or until study completion (60 months). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |